Autopsy report · NCT00509600
Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia
Cause of deathSlow enrollment
“Slow enrollment; study terminated.”
Life of this trial
- Registered 2 years 10 months after it had already started.
- Ran for about 4 years 7 months before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 1 year 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Leukemia
- Interventions
- Etanercept
- Participants
- 1
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Memantine and Antipsychotics Use
“Study terminated due to too slow enrollment” - A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
“Study has been terminated due to slow enrollment.” - Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
“Study terminated due to slower than anticipated enrollment.” - A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
“This study terminated prematurely because of slow enrollment” - Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs
“Study terminated due to slow enrollment and change in strategy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.